How grim is pancreatic cancer?

Weledji, Elroy Patrick; Enow-Orock, George; Mokake, Martin; Sinju, Motaze

doi:10.4081/oncol.2016.294

Cited by 34 publications

(34 citation statements)

References 88 publications

(133 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Globally, those numbers were 458,918 and 432,242, respectively, in 2018 . At the time of presentation, approximately 50% of patients have stage IV disease, and systemic therapies have a real but relatively modest impact on outcome . PDAC has the lowest 5‐year relative survival rate relative to all other solid tumor malignancies and is expected to become the second‐leading cause of cancer‐related death in the United States by 2030 .…”

Section: Pancreatic Cancermentioning

confidence: 99%

“…3 At the time of presentation, approximately 50% of patients have stage IV disease, and systemic therapies have a real but relatively modest impact on outcome. 4,5 PDAC has the lowest 5-year relative survival rate relative to all other solid tumor malignancies and is expected to become the second-leading cause of cancer-related death in the United States by 2030. 4 The high mortality rate of PDAC stems from multifactorial challenges related to the collective lack of early diagnosis and effective screening process, identification of high-risk patient groups, validated biomarkers, and effective treatment for advanced disease.…”

Section: Pancreatic Cancermentioning

confidence: 99%

“…4 The high mortality rate of PDAC stems from multifactorial challenges related to the collective lack of early diagnosis and effective screening process, identification of high-risk patient groups, validated biomarkers, and effective treatment for advanced disease. 5 Current systemic therapies available for unresectable locally advanced or metastatic PDAC have been shown to ameliorate symptoms experienced by patients and a valuable tool for supportive care. 6 Gourgou-Bourgade et al confirmed that FOLFIRINOX (fluorouracil, folinic acid, irinotecan, and oxaliplatin) significantly reduced health-related QoL impairment compared with gemcitabine, and both improved emotional functioning, pain, insomnia, anorexia, and constipation.…”

Section: Pancreatic Cancermentioning

confidence: 99%

See 2 more Smart Citations

Pancreatic cancer—A disease in need: Optimizing and integrating supportive care

Moffat

Epstein

O’Reilly

2019

Cancer

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that continues to be challenging to treat. PDAC has the lowest 5‐year relative survival rate compared with all other solid tumor malignancies and is expected to become the second‐leading cause of cancer‐related death in the United States by 2030. Given the high mortality, there is an increasing role for concurrent anticancer and supportive care in the management of patients with PDAC with the aims of maximizing length of life, quality of life, and symptom control. Emerging trends in supportive care that can be integrated into the clinical management of patients with PDAC include standardized supportive care screening, early integration of supportive care into routine cancer care, early implementation of outpatient‐based advance care planning, and utilization of electronic patient‐reported outcomes for improved symptom management and quality of life. The most common symptoms experienced are nausea, constipation, weight loss, diarrhea, anorexia, and abdominal and back pain. This review article includes current supportive management strategies for these and others. Common disease‐related complications include biliary and duodenal obstruction requiring endoscopic procedures and venous thromboembolic events. Patients with PDAC continue to have a poor prognosis. Systemic therapy options are able to palliate the high symptom burden but have a modest impact on overall survival. Early integration of supportive care can lead to improved outcomes.

show abstract

Section: Pancreatic Cancermentioning

confidence: 99%

Section: Pancreatic Cancermentioning

confidence: 99%

Section: Pancreatic Cancermentioning

confidence: 99%

See 1 more Smart Citation

Pancreatic cancer—A disease in need: Optimizing and integrating supportive care

Moffat

Epstein

O’Reilly

2019

Cancer

View full text Add to dashboard Cite

show abstract

“…Pancreatic cancer is the fourth leading cause of cancer-related deaths in the western world 7,8 . The most common form is pancreatic ductal adenocarcinoma (PDAC), with the majority of patients carrying activating KRAS oncogene mutations and mutation or deletion of the TP53 tumour suppressor 9 .…”

Section: Background and Summarymentioning

confidence: 99%

ROCK signalling induced gene expression changes in mouse pancreatic ductal adenocarcinoma cells

et al. 2016

View full text Add to dashboard Cite

The RhoA and RhoC GTPases act via the ROCK1 and ROCK2 kinases to promote actomyosin contraction, resulting in directly induced changes in cytoskeleton structures and altered gene transcription via several possible indirect routes. Elevated activation of the Rho/ROCK pathway has been reported in several diseases and pathological conditions, including disorders of the central nervous system, cardiovascular dysfunctions and cancer. To determine how increased ROCK signalling affected gene expression in pancreatic ductal adenocarcinoma (PDAC) cells, we transduced mouse PDAC cell lines with retroviral constructs encoding fusion proteins that enable conditional activation of ROCK1 or ROCK2, and subsequently performed RNA sequencing (RNA-Seq) using the Illumina NextSeq 500 platform. We describe how gene expression datasets were generated and validated by comparing data obtained by RNA-Seq with RT-qPCR results. Activation of ROCK1 or ROCK2 signalling induced significant changes in gene expression that could be used to determine how actomyosin contractility influences gene transcription in pancreatic cancer.

show abstract

“…Pancreatic cancer (i.e., pancreatic ductal adenocarcinoma, PDAC) is an important healthcare issue and a highly lethal disease (1)(2)(3). Thus, more than 50% of patients present distant metastases at diagnosis and the estimated 5-year survival rate for all stages is around 8% (4).…”

Section: Introductionmentioning

confidence: 99%

Is Hepatitis B Virus a Player in Pancreatic Cancer?

Dumitraşcu¹,

Pineau²

2018

chr

View full text Add to dashboard Cite

Pancreatic cancer (i.e., pancreatic ductal adenocarcinoma, PDAC) is an important healthcare issue and a highly lethal disease. Thus, almost 80% of patients with PDAC will die within one year after diagnosis. Several factors including smoking, obesity, advanced age, diabetes mellitus and chronic pancreatitis have been associated with increased risk of PDAC. Hepatitis B virus (HBV) infection is also considered as a risk factor for PDAC development in some studies. However, the role of HBV infection in PDAC is poorly explored. The present paper reviews the current relevant literature exploring the impact of HBV infection in PDAC. Assessment of HBV infection impact in PDAC is challenging because its effects could be easily underestimated. Indeed, the role played by occult B infection (OBI) and intrinsic difficulties to detect HBV antigens or DNA in pancreatic tissue remains major limitations to further progress. To date a significant proportion of available literature suggests the potential oncogenic role of HBV in PDAC but experimental evidences remain scarce. Remarkably, it appears that HBV infection might influence some clinical and pathological features of patients with PDAC. Future researches to better define the role of HBV infection in developing PDAC are urgently needed.

show abstract

How grim is pancreatic cancer?

Cited by 34 publications

References 88 publications

Pancreatic cancer—A disease in need: Optimizing and integrating supportive care

Pancreatic cancer—A disease in need: Optimizing and integrating supportive care

ROCK signalling induced gene expression changes in mouse pancreatic ductal adenocarcinoma cells

Is Hepatitis B Virus a Player in Pancreatic Cancer?

Contact Info

Product

Resources

About